Delivery Order SPE2DB22D3301-SPE2DB25FY8RS
- Not listed
- The Defense Logistics Agency awarded a $27,926.40 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Gamunex-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price contract is set to be completed by August 21, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. Gamunex-C is an intravenous immunoglobulin product used to treat immunodeficiency disorders and certain autoimmune...
- The Defense Logistics Agency awarded a $11,636.00 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) therapy used to treat various immunodeficiency and autoimmune conditions, making it a critical...
- The Defense Logistics Agency awarded a delivery order valued at $23.6K to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of GAMUNEX-C (20 gram/200 mL vial, 200 mL units). GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used to treat immunodeficiency disorders and other immune-related conditions. This is a firm fixed-price delivery order with no set-aside designation, issued under AmerisourceBergen's existing contract vehicle with DLA. The order is scheduled for...
- The Defense Logistics Agency awarded a $23,272.00 delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 40 Gram/400 ML vials. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by September 3, 2025. GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used to treat various immunological conditions and is a critical pharmaceutical commodity within the federal medical supply chain. The contract is performed at...
- The Defense Logistics Agency awarded a $4,555.05 delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 5 gram/50 milliliter vials on August 1, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gamunex-C 10 gram/100 mL vials with a ceiling value of $3,662.82. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Gamunex-C is an intravenous immunoglobulin therapy used to treat immune deficiency disorders and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 40 Gram/400 mL vials, valued at $4,654.40 with a firm fixed price structure. This is an unset-aside, competitively awarded contract with an ultimate completion date of August 20, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used to treat primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with firm fixed pricing. This is a non-set-aside delivery order with an ultimate completion date of September 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is executing this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of GAMUNEX-C 10 gram/100 milliliter vials, with a ceiling value of $9,157.05 and an ultimate completion date of August 22, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin used to treat immunodeficiency and autoimmune...
- The Defense Logistics Agency awarded a $41,178.10 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This competitively awarded, firm fixed-price contract is non-set-aside and scheduled for completion by August 21, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an immune globulin intravenous (human) product used in treating immune deficiency disorders and is a critical pharmaceutical...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY8RSDelivery Order
The Defense Logistics Agency awarded a $14,161.68 firm fixed price delivery order to AmerisourceBergen Drug Corp for Gamunex-C 20 gram/200 mL vials on July 31, 2025, with an ultimate completion date of August 21, 2025. Gamunex-C is an intravenous immunoglobulin (IVIG) therapy used to treat immunodeficiency disorders and various autoimmune conditions. This is a non-set-aside competitive award executed against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems. This delivery order represents a routine transaction under AmerisourceBergen's SPE2DX indefinite delivery contract with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The company's demonstrated capability to fulfill federal medical supply requirements through competitive procurement and its established relationship with DLA positions it as a primary pharmaceutical vendor for Department of Defense medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 7/31/25 |